5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | NEUTRAL | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 3.43▼ | 3.43▼ | 3.43▼ | 3.42▲ | 3.40▲ |
MA10 | 3.43▼ | 3.43▼ | 3.43▼ | 3.40▲ | 3.34▲ |
MA20 | 3.43▼ | 3.43▼ | 3.43▼ | 3.39▲ | 3.11▲ |
MA50 | 3.43▼ | 3.42▲ | 3.41▲ | 3.29▲ | 2.94▲ |
MA100 | 3.42▲ | 3.41▲ | 3.40▲ | 3.08▲ | 3.05▲ |
MA200 | 3.41▲ | 3.39▲ | 3.38▲ | 2.92▲ | 2.90▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▼ | -0.001▼ | -0.001▼ | -0.005▼ | 0.032▲ |
RSI | 35.547▼ | 48.352▼ | 53.892▲ | 74.224▲ | 71.103▲ |
STOCH | 75.000 | 75.000 | 75.000 | 81.111▲ | 95.094▲ |
WILL %R | -50.000 | -50.000 | -50.000 | -25.000▲ | -3.636▲ |
CCI | -180.303▼ | -190.123▼ | -97.576 | 128.889▲ | 74.267 |
Tuesday, October 22, 2024 04:58 PM
(ETF Architect) -- EA Series Trust announces that the following funds will move their primary listings to the New York Stock Exchange: Strive U.S. Energy ETF (NYSE Arca: DRLL), Strive 500 ETF (NYSE ...
|
Tuesday, October 22, 2024 10:55 AM
Revance Therapeutics, Inc. (NASDAQ: RVNC )'s sale to Crown Laboratories, Inc. for $6.66 per share in cash. If you are a Revance shareholder, click here to learn more about your rights and options .
|
Tuesday, October 22, 2024 10:53 AM
ARC Capital Venture LLC has identified a growing wave of opportunity within the fixed-income investment market, as stabilizing economic conditions provide a more favorable environment for investors ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
22/10/24 | 3.41 | 3.44 | 3.41 | 3.42 | 310,403 |
21/10/24 | 3.41 | 3.43 | 3.41 | 3.42 | 105,588 |
18/10/24 | 3.41 | 3.43 | 3.41 | 3.42 | 78,346 |
17/10/24 | 3.40 | 3.42 | 3.40 | 3.41 | 203,038 |
16/10/24 | 3.41 | 3.42 | 3.39 | 3.42 | 844,872 |
15/10/24 | 3.38 | 3.40 | 3.38 | 3.40 | 75,957 |
14/10/24 | 3.41 | 3.41 | 3.38 | 3.39 | 256,957 |
11/10/24 | 3.38 | 3.40 | 3.38 | 3.39 | 51,943 |
10/10/24 | 3.41 | 3.41 | 3.39 | 3.39 | 96,835 |
09/10/24 | 3.41 | 3.41 | 3.38 | 3.39 | 122,587 |
|
|
||||
|
|
||||
|
|